2nd Jun 2008 07:00
PuriCore Annual Report and Accounts
Proposed Amendments to Articles of Association
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 2 June 2008 - PuriCore (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, today announces that its annual report and accounts, containing proposed amendments to the articles of association, have been posted to shareholders and will be available for inspection shortly at the UKLA's Document Viewing Facility, which is situated at:
UKLA Document Viewing Facility
25 The North Colonnade
Canary Wharf
London
E14 5HS
Additionally, the report can be viewed on PuriCore's investor relations website at http://investor.puricore.com shortly or at PuriCore's UK office (Wolseley House, Dyson Way, Staffordshire Technology Park, Beaconside, Stafford ST18 OGA) shortly before and during the Annual General Meeting scheduled to commence at 9am on 26 June 2008.
|
Enquiries: |
|
|
Ben Brewerton |
Greg Bosch, CEO |
|
Susan Quigley |
Keith A. Goldan, CFO |
|
Financial Dynamics |
PuriCore |
|
+44 (0) 20 7831 3113 |
+1 484 321 2700 |
About PuriCore
PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, Avian Influenza, HIV, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
Related Shares:
RLM.L